You can always press Enter⏎ to continue
Initial Eligibility Survey (Beckley)

Initial Eligibility Survey (Beckley)

Hi there, please fill out and submit this form to assess your eligibility.
13Questions
  • 1

    Kadima Neuropsychiatry Institute specializes in providing advanced treatments for mental health. We are also conducting research to develop innovative new treatments, such as psychedelics.

    KADIMA is seeking participants for a clinical study of the
    investigational drug BPL-003 (aka 5-MeO-DMT) for Treatment-Resistant Depression (TRD).

    The principal investigator at our site is DAVID FEIFEL, MD, Ph.D.

    The following survey will assess your current eligibility to participate in this trial. This survey should take approximately 3 minutes to complete.
    Please answer as honestly and as completely as possible.

    This survey platform is HIPAA-compliant and designed to protect your protected health information (PHI).
    Information entered will only be used for the purposes of eligibility assessment by KADIMA Research Staff members. 

     

    Press
    Enter
  • 2
    Press
    Enter
  • 3
    -
    Pick a Date
    Press
    Enter
  • 4
    Press
    Enter
  • 5
    Press
    Enter
  • 6
    Press
    Enter
  • 7
    Press
    Enter
  • 8
    Press
    Enter
  • 9
    1 of 2
    Press
    Enter
  • 10
    Press
    Enter
  • 11
    Press
    Enter
  • 12
    Press
    Enter
  • 13
    Press
    Enter
  • 14
    • Huge
    • Large
    • Normal
    • Small
    Ok
    quoteCreated with Sketch.
    Ok
    Press
    Enter
  • 15
    Your information will be kept in a HIPAA-compliant database. You can contact us anytime at research@kadimanp.com to have your information removed.
    Press
    Enter
  • 16
    Press
    Enter
  • Should be Empty:
Question Label
1 of 16See AllGo Back
close